
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics is poised for success as evidenced by their strong launch of Icotyde in PoS, positive PK data and initiation of new programs, as well as a solid financial position with multiple low-risk future milestone payments. With a first-in-class lead asset, a strong platform, and a potentially multi-billion dollar market opportunity, Protagonist Therapeutics is undervalued and poised for continued stock outperformance. Investors should closely monitor the progress of the Ico launch and data releases from Protagonist's own programs for potential upside.
Bears say
Protagonist Therapeutics is expected to have strong upcoming milestones, including the potential FDA approval of rusfertide for polycythemia vera, which could result in significant milestone payments. However, there is ongoing competition in the market with the entry of other biologics, which could limit the success of Icotyde. The company's current positive financial situation is largely dependent on milestone payments, as their own IL-17 and obesity programs have not been included in their valuation. These factors, along with potential challenges in the market, contribute to the negative outlook on the stock.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares